In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Immunic (IMUX – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.63.
According to TipRanks, Argyrides is an analyst with an average return of -0.8% and a 35.48% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Immunic, and Unity Biotechnology.
Immunic has an analyst consensus of Moderate Buy, with a price target consensus of $16.50, representing a 912.27% upside. In a report released on April 21, Piper Sandler also assigned a Buy rating to the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $11.76 and a one-year low of $1.11. Currently, Immunic has an average volume of 1.34M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunic, Inc. engages in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.
Read More on IMUX:
